Lirentelimab safe, effective in long-term gastritis, duodenitis treatment

Lirentelimab safe, effective in long-term gastritis, duodenitis treatment

Lirentelimab was safe and effective in the long-term treatment of patients with eosinophilic gastritis and/or eosinophilic duodenitis, according to a presentation at UEG Week.“Lirentelimab, previously called AK002, is a humanized monoclonal antibody that targets a receptor called siglec-8 that’s highly specific in eosinophils and mast cells. When this receptor is activated, it creates an inhibitory signal that leads to eosinophil depletion and mast cell inhibition,” Evan S. Dellon, MD, MPH, of the University of North Carolina School of Medicine at Chapel Hill, said. “ENIGMARead More

Share on facebook
Share on twitter
Share on linkedin